Nigella Sativa cardioprotective effect in Type 1 diabetes

Possible cardioprotective effect of Nigella Sativa in Type 1 diabetes

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202302478939306

Enrollment

Registered

2023-02-06

Start date

2023-02-15

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutritional, Metabolic, Endocrine Paediatrics

Interventions

Treatment group with Nigella Sativa

none

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 1 diabetes children and adolescents with age 6-18 years

Exclusion criteria

Exclusion criteria: Clinical evidence of heart failure coronary artery disease systemic hypertension rheumatic fever cardiomyopathy, The use of any medication other than insulin known to affect cardiac function (such as digitalis, angiotensin converting enzyme inhibitor, or ß-blocker)

Design outcomes

Primary

Measure	Time frame
Cardiac function by echocardiography	—

Secondary

Measure	Time frame
Serum level of malondialdhyde, nitric oxide, TNF-a and the cardiac marker troponin I.	—

Countries

Egypt

Contacts

Public ContactWael El Feky

Professor of Cardiothoracic surgery

waelfeky@yahoo.com00201004332200

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026